Spero Therapeutics Inc (SPRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 66,802 | 47,977 | 103,781 | 53,509 | 18,256 |
| Gross Profit | 66,802 | 47,977 | 103,781 | 53,509 | 18,256 |
| Operating Expenses | 60,488 | 121,338 | 82,300 | 95,706 | 106,227 |
| Operating Income | 6,314 | -73,361 | 21,481 | -42,197 | -87,971 |
| Interest Expense | 0 | 0 | 0 | 2,605 | 1,940 |
| Other Income | 2,519 | 4,795 | 3,923 | -1,613 | 155 |
| Pre-tax Income | 8,833 | -68,566 | 25,404 | -46,415 | -89,756 |
| Income Tax | 261 | N/A | 2,598 | N/A | N/A |
| Net Income Continuous | 8,572 | -68,566 | 22,806 | -46,415 | -89,756 |
| Net Income | $8,572 | $-68,566 | $22,806 | $-46,415 | $-89,756 |
| EPS Basic Total Ops | 0.15 | -1.27 | 0.43 | -1.23 | -2.91 |
| EPS Basic Continuous Ops | 0.15 | -1.27 | 0.43 | -1.23 | -2.91 |
| EPS Diluted Total Ops | 0.15 | -1.27 | 0.43 | -1.23 | -2.91 |
| EPS Diluted Continuous Ops | 0.15 | -1.27 | 0.43 | -1.23 | -2.91 |
| EPS Diluted Before Non-Recurring Items | N/A | -1.27 | 0.51 | -1.23 | -2.91 |
| EBITDA(a) | $6,314 | $-73,359 | $21,848 | $-41,328 | $-87,325 |